REMINDER: THE ARENA PLATFORM, INC. has no obligation to monitor the Forums. However, THE ARENA PLATFORM, INC. reserves the right to review any materials submitted to or posted on the Forums, and remove, delete, redact or otherwise modify such materials, in its sole discretion and for any reason whatsoever, at any time and from time to time, without notice or further obligation to you. THE ARENA PLATFORM, INC. has no obligation to display or post any materials provided by you. THE ARENA PLATFORM, INC. reserves the right to disclose, at any time and from time to time, any information or materials that we deem necessary or appropriate to satisfy any applicable law, regulation, contract obligation, legal or dispute process or government request. Click on the following hyperlinks to further read the applicable Privacy Policy and Terms of Use.
JRE #1671
- Thread starter Duffy LaCoronilla
- Start date
I’m curious to the validity of you image due to nothing coming up in any search and my friends in Mex having no idea what you’re talking about, despite it being “sent out to everyone”.
that doesn’t take much “reading into it”.
He made up the "everyone." Dude's a psychopath, period. Psychopaths are liars.
Not "are paying for," but have paid for.
January 15, 2022
The Reason Insurers Cover Unproven Medication
Thomas Hilton, PhD | Retired, NIH
While it seems irrational to pay for medication that is ineffective, the cost in the case of ivermectin is below annual premium rates - i.e., still profitable. Given the drug's political baggage, failing to pay claim risks permanently alienating both current and potential clients. Had the cost been much higher, claims might have been rejected, just as we have seen reticence to cover the cost of aducanumab, which is also of comparablt dubious effectiveness but costs the price of a new car.
--------
January 16, 2022
Business case for prior-authorization
David Anderson, MSPPM | Duke University Department of Population Health Sciences
The business case for any single insurer to institute a prior authorizatoin requirement or other prescription limitations for ivermectin, and other fad drugs for COVID, is not as straightforward as the authors seem to imply with the sentence " Findings suggest that insurers heavily subsidized the costs of ivermectin prescriptions for COVID-19, even though economic theory holds that insurers should not cover ineffective care." The authors estimate a $129,000,000 excess cost for ivermectin in a single year for Medicare Advantage and privately insured patients. Using KFF 2019 coverage estimates, this is between 56% to 61% of the population depending on how the ACA marketplace coverage is counted. At 56% of the population, the per member per month (PMPM) cost is less than $0.06 PMPM. There are real costs to set up and administer holds. Large insurers may be able to amortize the costs over sufficient number of denied claims to justify the hurdle costs.
There are two other factors that may be related to the continued payment of claims for an ineffective treatment. First, if insurers assume that ivermectin prescriptions will resemble the trajectory of hydroxychloroquine where there was a significant spike and then a rapid fade as new evidence on ineffectiveness was presented (1), the PMPM of plausible savings would decrease. Secondly, COVID has become heavily polarized and politicized including the prescription of ineffective folk cures (2). Insurers may be motivated to minimize media attention on a matter that has no material effect on premiums.
References
1. Bull-Otterson L, Gray EB, Budnitz DS, et al. Hydroxychloroquine and Chloroquine Prescribing Patterns by Provider Specialty Following Initial Reports of Potential Benefit for COVID-19 Treatment - United States, January-June 2020. MMWR Morb Mortal Wkly Rep 2020;69(35):1210-1215. Published 2020 Sep 4. doi:10.15585/mmwr.mm6935a4
2. Harrigan, J.J., Hubbard, R.A., Thomas, S. et al. Association Between US Administration Endorsement of Hydroxychloroquine for COVID-19 and Outpatient Prescribing. J Gen Intern Med 35;2826–2828 (2020). https://doi.org/10.1007/s11606-020-05938-4.
---------
It would be difficult to be as dishonest as you are. Who could tolerate you
pretty much the whole world has agreed that the data shows that Ivermectin is not useful
no one is using it anymore....not even the third world
but here's Duffy still shitting his diaper over a therapeutic that does not work while whinging about vaccines that drastically reduce symptoms and likelihood of hospitalization/death
please join us in 2022, Duffy
no one is using it anymore....not even the third world
but here's Duffy still shitting his diaper over a therapeutic that does not work while whinging about vaccines that drastically reduce symptoms and likelihood of hospitalization/death
please join us in 2022, Duffy
When the gullible get fooled there is no convincing them otherwise,
But but but
www.newsweek.com
Fire Chief Dies of COVID Hours After Family Wins Fight to Use Ivermectin
The family of Wayne Doyle had wanted the drug to be part of his care plan, but the hospital reportedly refused to administer it.
www.newsweek.com
I'm shocked you posted bad info. Shocked!
I missed the official end of the hydroxy talking point and now you're telling me ivermectin is done?
It's about belonging, about being part of a group. About solidarity. I've never met an anti-covid vaxxer who reconsidered the evidence and got vaccinated. (Though I'm sure some have). I think that they appreciate being part of a group and don't want to lose that group identity.
Clinical trials are ongoing.
/cloudfront-us-east-2.images.arcpublishing.com/reuters/ILJZNGVNLRPQ7BLVHAQCU7UW3I.jpg)
Ivermectin shows ‘antiviral effect’ against COVID, Japanese company says
Japanese trading and pharmaceuticals company Kowa Co Ltd on Monday said that anti-parasite drug ivermectin showed an "antiviral effect" against Omicron and other coronavirus variants in joint non-clinical research.
www.reuters.com
I have always said that I don’t know whether or not ivermectin works. I’m just not of the mind to immediately declare it bad, dangerous, horse paste.
Again, clinical trials are ongoing (including one being done by the NIH).
This is from the NIH (last august)…
Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines
Repurposed medicines may have a role against the SARS-CoV-2 virus. The antiparasitic ivermectin, with antiviral and anti-inflammatory properties, has now been tested in numerous clinical trials.We assessed the efficacy of ivermectin treatment in reducing ...
www.ncbi.nlm.nih.gov
This one published a month earlier couldn’t make any conclusions that it was effective.
Ivermectin for preventing and treating COVID-19 - PubMed
Based on the current very low- to low-certainty evidence, we are uncertain about the efficacy and safety of ivermectin used to treat or prevent COVID-19. The completed studies are small and few are considered high quality. Several studies are underway that may produce clearer answers in review...
pubmed.ncbi.nlm.nih.gov